Prakash Investment Advisors LLC Takes $283,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Prakash Investment Advisors LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,800 shares of the company’s stock, valued at approximately $283,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB grew its position in shares of Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% during the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the period. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company’s stock worth $47,000 after purchasing an additional 388 shares in the last quarter. Finally, EMC Capital Management boosted its position in shares of Moderna by 311.2% during the 4th quarter. EMC Capital Management now owns 1,250 shares of the company’s stock worth $52,000 after purchasing an additional 946 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $40.00 price target on shares of Moderna in a research report on Tuesday. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday, January 16th. Bank of America cut their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Wolfe Research initiated coverage on shares of Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Finally, Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $60.63.

Insider Buying and Selling at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 2,664 shares of company stock worth $115,210 in the last ninety days. 15.70% of the stock is owned by insiders.

Moderna Trading Down 6.0 %

MRNA opened at $33.73 on Friday. The firm has a market capitalization of $12.98 billion, a PE ratio of -3.63 and a beta of 1.59. The firm’s 50-day moving average price is $38.17 and its 200 day moving average price is $53.20. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.